Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines. We’ve been pioneering RNAi therapeutics since 2002 and are excited to share our ongoing scientific progress.
On November 19, 2021, we hosted a virtual R&D Day event showcasing Alnylam’s late stage clinical efforts, next wave programs, and platform advances. The event included presentations from Alnylam senior leaders as well as guest speakers.
To view the webcast, click here.
To view the R&D Day presentation, click here.
Positive interim findings from the ongoing Phase 1 study of zilebesiran (formerly known as ALN-AGT) in adults with hypertension were presented during the American Heart Association (AHA) Scientific Sessions 2021 (Nov. 13-15).
Positive results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1), were presented as part of the late-breaking session at the American Society of Nephrology (ASN) Kidney Week 2021 virtual meeting held on November 4-7.
The POWER study (POrphyria Worldwide Patient Experience Research) surveyed 92 patients living with acute hepatic porphyria (AHP) around the world to bring to light the emotional, mental, and physical burden of AHP on the individual and their social circle. Survey participants reported substantial emotional burden associated with AHP, citing moderate to severe depression and anxiety. They also reported significant pain levels and work impairment. These data are being presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2021. Encore 24-month interim data from the open-label extension period of the ENVISION Phase 3 study of GIVLAARI® (givosiran) in patients with AHP will also presented, along with additional findings on the burden of AHP.
Positive findings from a 24-month interim analysis of the ongoing open-label extension (OLE) period of the ENVISION Phase 3 study of GIVLAARI® (givosiran) in patients with acute hepatic porphyria (AHP) were presented during the United European Gastroenterology (UEG) Week Virtual 2021 (Oct. 3-5). The data further confirm that long-term dosing with GIVLAARI provides sustained and continuous benefit to patients with AHP while maintaining an acceptable safety profile. Findings on the burden of AHP from the ENVISION Phase 3 study and from Part B of the EXPLORE study were also presented.
On October 1, 2021, we hosted an online RNAi Roundtable to review the progress with our CNS and extrahepatic RNAi pipeline programs.
Access the replay
View the presentation
Vasant Jadhav, Ph.D.
Senior Vice President, Research
Kirk Brown, Ph.D.
Senior Director, CNS Program
Bret Bostwick, M.D.
Director, Clinical Research
We presented progress on our RNAi therapeutics platform efforts at the Oligonucleotide Therapeutics Society (OTS) 2021 Annual Meeting.
Harnessing RNAi for a New Class of Medicines – John Maraganore
Expanding the Reach of RNAi Therapeutics – Kirk Brown
Development of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 – Pushkal Garg
On September 20, 2021, we hosted an online RNAi Roundtable to review the progress with our liver-directed RNAi pipeline programs.
New kidney stone data from ongoing clinical trials of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 – the gene encoding glycolate oxidase – for the treatment of primary hyperoxaluria type 1 (PH1), were presented at the American Urological Association (AUA) Annual Meeting, held virtually September 10-13, 2021. Results from the Phase 1/2 clinical trial of lumasiran and its Phase 2 open-label extension (OLE) period showed that treatment with lumasiran led to an apparent reduction in kidney stone related adverse events in pediatric and adult patients with PH1. A reduction in kidney stone event (KSE) rates – an exploratory endpoint in ILLUMINATE-A and ILLUMINATE-B Phase 3 trials – was reported in ILLUMINATE-A at Month 12, with KSE rates remaining stable through Month 6 in ILLUMINATE-B.
Additional positive 9-month results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with polyneuropathy, were presented at the 3rd EU-ATTR Amyloidosis Meeting. Subgroup analyses and exploratory endpoints demonstrated that vutrisiran improved important areas of patient health and function compared with placebo at 9 months. Additional analyses showed similar improvements in progression of neuropathy and quality of life measures with vutrisiran compared with placebo, regardless of prior TTR stabilizer use.
